Logo image of VANI

VIVANI MEDICAL INC (VANI) Stock Price, Forecast & Analysis

USA - NASDAQ:VANI - US92854B1098 - Common Stock

1.5 USD
+0.07 (+4.9%)
Last: 11/12/2025, 1:17:00 PM

VANI Key Statistics, Chart & Performance

Key Statistics
Market Cap88.86M
Revenue(TTM)N/A
Net Income(TTM)-25.54M
Shares59.24M
Float30.19M
52 Week High1.92
52 Week Low0.91
Yearly DividendN/A
Dividend YieldN/A
EPS(TTM)-0.45
PEN/A
Fwd PEN/A
Earnings (Next)11-18 2025-11-18
IPO2014-12-05
Sector
GICS SectorHealth Care
GICS IndustryHealth Care Equipment & Supplies
GICS IndustryGroupHealth Care Equipment & Services
GICS SubIndustryHealth Care Equipment


VANI short term performance overview.The bars show the price performance of VANI in the last week, last 2 weeks, last month, last 3 and 6 months. 1 week 2 week 1 month 3 months 6 months 0 10 -10 20 30

VANI long term performance overview.The bars show the price performance of VANI in the last 1, 2 and 3 years. 1 year 2 years 3 years 10 20 30 40 50

The current stock price of VANI is 1.5 USD. In the past month the price increased by 8.33%. In the past year, price increased by 9.16%.

VIVANI MEDICAL INC / VANI Daily stock chart

VANI Latest News, Press Relases and Analysis

VANI Competitors/Peers

The largest stocks on the US markets in the "Health Care Equipment" sub-industry
Full List
Symbol
Company Name
TA
FA
PE
Market Cap
ABT ABBOTT LABORATORIES 25.73 223.47B
ISRG INTUITIVE SURGICAL INC 66.4 204.96B
BSX BOSTON SCIENTIFIC CORP 35.24 154.03B
SYK STRYKER CORP 28.11 141.56B
IDXX IDEXX LABORATORIES INC 56.73 57.23B
BDX BECTON DICKINSON AND CO 13.3 54.99B
EW EDWARDS LIFESCIENCES CORP 33.29 50.23B
RMD RESMED INC 25.6 36.99B
GEHC GE HEALTHCARE TECHNOLOGY 16.21 33.96B
PODD INSULET CORP 73.67 23.70B
DXCM DEXCOM INC 32.03 23.36B
ZBH ZIMMER BIOMET HOLDINGS INC 11.1 17.78B

About VANI

Company Profile

VANI logo image Vivani Medical, Inc. is a preclinical stage biopharmaceutical company, which engages in the business of developing miniaturized, subdermal implants utilizing proprietary NanoPortal technology to enable long-term, near constant-rate delivery of a broad range of medicines to treat chronic diseases. The company is headquartered in Alameda, California and currently employs 42 full-time employees. The company went IPO on 2014-12-05. Leveraging its NanoPortal platform, it develops biopharmaceutical implants designed to deliver drug molecules steadily over extended periods of time with the goal of guaranteeing adherence, and to improve patient tolerance to their medication. Its lead program, NPM-115, is a six-month, subdermal, GLP-1 (exenatide) implant under development for chronic weight management in overweight individuals. Its pipeline includes NPM-139 (semaglutide implant), which is also under development for chronic weight management. NPM-119 refers to its six-month, subdermal, GLP-1 (exenatide) implant under development for the treatment of type 2 diabetes. These NanoPortal implants are designed to provide patients with the opportunity to realize the benefit of their medication by avoiding the challenges associated with the daily or weekly administration of orals and injectables.

Company Info

VIVANI MEDICAL INC

1350 S. Loop Road

Alameda CALIFORNIA US

Employees: 37

VANI Company Website

VANI Investor Relations

Phone: 14155068462

VIVANI MEDICAL INC / VANI FAQ

Can you describe the business of VIVANI MEDICAL INC?

Vivani Medical, Inc. is a preclinical stage biopharmaceutical company, which engages in the business of developing miniaturized, subdermal implants utilizing proprietary NanoPortal technology to enable long-term, near constant-rate delivery of a broad range of medicines to treat chronic diseases. The company is headquartered in Alameda, California and currently employs 42 full-time employees. The company went IPO on 2014-12-05. Leveraging its NanoPortal platform, it develops biopharmaceutical implants designed to deliver drug molecules steadily over extended periods of time with the goal of guaranteeing adherence, and to improve patient tolerance to their medication. Its lead program, NPM-115, is a six-month, subdermal, GLP-1 (exenatide) implant under development for chronic weight management in overweight individuals. Its pipeline includes NPM-139 (semaglutide implant), which is also under development for chronic weight management. NPM-119 refers to its six-month, subdermal, GLP-1 (exenatide) implant under development for the treatment of type 2 diabetes. These NanoPortal implants are designed to provide patients with the opportunity to realize the benefit of their medication by avoiding the challenges associated with the daily or weekly administration of orals and injectables.


What is the stock price of VIVANI MEDICAL INC today?

The current stock price of VANI is 1.5 USD. The price increased by 4.9% in the last trading session.


Does VANI stock pay dividends?

VANI does not pay a dividend.


What is the ChartMill rating of VIVANI MEDICAL INC stock?

VANI has a ChartMill Technical rating of 7 out of 10 and a ChartMill Fundamental rating of 1 out of 10.


Can you provide the market cap for VIVANI MEDICAL INC?

VIVANI MEDICAL INC (VANI) has a market capitalization of 88.86M USD. This makes VANI a Micro Cap stock.


Can you provide the upcoming earnings date for VIVANI MEDICAL INC?

VIVANI MEDICAL INC (VANI) will report earnings on 2025-11-18.


Can you provide the ownership details for VANI stock?

You can find the ownership structure of VIVANI MEDICAL INC (VANI) on the Ownership tab.


VANI Technical Analysis

ChartMill assigns a technical rating of 7 / 10 to VANI. When comparing the yearly performance of all stocks, VANI is one of the better performing stocks in the market, outperforming 72.13% of all stocks.


Chartmill TA Rating
Chartmill Setup Rating

VANI Fundamental Analysis

ChartMill assigns a fundamental rating of 1 / 10 to VANI. The financial health of VANI is average, but there are quite some concerns on its profitability.


Chartmill FA Analysis
Valuation
Growth
Profitability
Health
Dividend

VANI Financial Highlights

Over the last trailing twelve months VANI reported a non-GAAP Earnings per Share(EPS) of -0.45. The EPS increased by 4.26% compared to the year before.


Industry RankSector Rank
PM (TTM) N/A
ROA -88.35%
ROE -520.1%
Debt/Equity 0
Chartmill High Growth Momentum
EPS Q2Q%-20%
Sales Q2Q%N/A
EPS 1Y (TTM)4.26%
Revenue 1Y (TTM)N/A

VANI Forecast & Estimates

8 analysts have analysed VANI and the average price target is 5.1 USD. This implies a price increase of 240% is expected in the next year compared to the current price of 1.5.


Analysts
Analysts82.5
Price Target5.1 (240%)
EPS Next Y-0.84%
Revenue Next YearN/A

VANI Ownership

Ownership
Inst Owners6.84%
Ins Owners48.99%
Short Float %0.81%
Short Ratio1.28